Amgen Inc. scored a small victory today when EU regulators approved its experimental drug for secondary hyperparathyroidism in patients with chronic kidney disease on dialysis. The approval also covers elevated calcium levels in patients with cancers of the parathyroid gland, a rather rare condition. The drug is already approved in the US, where it has been sold as Sensipar since March.
